This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, M. S.
Right arrow Articles by Iwamoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, M. S.
Right arrow Articles by Iwamoto, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2008, p. 4228-4232, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00487-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects{triangledown}

Matt S. Anderson,1* Thomas N. Kakuda,2 William Hanley,1 Jutta Miller,1 James T. Kost,1 Randall Stoltz,4 Larissa A. Wenning,1 Julie A. Stone,1 Richard M. W. Hoetelmans,3 John A. Wagner,1 and Marian Iwamoto1

Department of Clinical Pharmacology, Merck & Co., Inc., Whitehouse Station, New Jersey,1 Tibotec Inc., Yardley, Pennsylvania,2 Tibotec BVBA, Mechelen, Belgium,3 Covance GFI Research, Evansville, Indiana4

Received 14 April 2008/ Returned for modification 2 August 2008/ Accepted 28 September 2008

Etravirine, a next-generation nonnucleoside reverse transcriptase inhibitor, and raltegravir, an integrase strand transfer inhibitor, have separately demonstrated potent activity in treatment-experienced, human immunodeficiency virus (HIV)-infected patients. An open-label, sequential, three-period study with healthy, HIV-seronegative subjects was conducted to assess the two-way interaction between etravirine and raltegravir for potential coadministration to HIV-infected patients. In period 1, 19 subjects were administered 400 mg raltegravir every 12 h (q12 h) for 4 days, followed by a 4-day washout; in period 2, subjects were administered 200 mg etravirine q12 h for 8 days; and in period 3, subjects were coadministered 400 mg raltegravir and 200 mg etravirine q12 h for 4 days. There was no washout between periods 2 and 3. Doses were administered with a moderate-fat meal. Etravirine had only modest effects on the pharmacokinetics of raltegravir, while raltegravir had no clinically meaningful effect on the pharmacokinetics of etravirine. For raltegravir coadministered with etravirine relative to raltegravir alone, the geometric mean ratio (GMR) and 90% confidence interval (CI) were 0.90 and 0.68 to 1.18, respectively, for the area under the concentration curve from 0 to 12 h (AUC0-12), 0.89 and 0.68 to 1.15, respectively, for the maximum concentration of drug in serum (Cmax), and 0.66 and 0.34 to 1.26, respectively, for the trough drug concentration (C12); the GMR (90% CI) for etravirine coadministered with raltegravir relative to etravirine alone was 1.10 (1.03, 1.16) for AUC0-12, 1.04 (0.97, 1.12) for Cmax, and 1.17 (1.10, 1.26) for C12. All drug-related adverse clinical experiences were mild and generally transient in nature. No grade 3 or 4 adverse experiences or discontinuations due to adverse experiences occurred. Coadministration of etravirine and raltegravir was generally well tolerated; the data suggest that no dose adjustment for either drug is necessary.

* Corresponding author. Mailing address: Department of Clinical Pharmacology, Merck & Co., Inc., RY34A-500, P.O. Box 2000, Rahway, NJ 07065. Phone: (732) 594-3801. Fax: (732) 594-5405. E-mail: matt_anderson{at}merck.com

{triangledown} Published ahead of print on 6 October 2008.

Antimicrobial Agents and Chemotherapy, December 2008, p. 4228-4232, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00487-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Loutfy, M., Ribera, E., Florence, E., De Wit, S., Castagna, A., Ryan, R., Hill, A., Vanaken, H., van Delft, Y., Marks, S. (2009). Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother 64: 1341-1344 [Full Text]  
  • van Luin, M., Colbers, A., Verwey-van Wissen, C. P. W. G. M., van Ewijk-Beneken-Kolmer, E. W. J., van der Kolk, M., Hoitsma, A., da Silva, H. G., Burger, D. M. (2009). The Effect of Raltegravir on the Glucuronidation of Lamotrigine. J Clin Pharmacol 49: 1220-1227 [Abstract] [Full Text]  
  • Hanley, W. D., Wenning, L. A., Moreau, A., Kost, J. T., Mangin, E., Shamp, T., Stone, J. A., Gottesdiener, K. M., Wagner, J. A., Iwamoto, M. (2009). Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir. Antimicrob. Agents Chemother. 53: 2752-2755 [Abstract] [Full Text]  
  • Wittkop, L., Breilh, D., Da Silva, D., Duffau, P., Mercie, P., Raymond, I., Anies, G., Fleury, H., Saux, M.-C., Dabis, F., Fagard, C., Thiebaut, R., Masquelier, B., Pellegrin, I. (2009). Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 63: 1251-1255 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»